This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2017 Mar 14;317(10):1075-1077.

doi: 10.1001/jama.2016.20644.

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year

Rebecca L Winslow¹, Iain D Milligan¹, Merryn Voysey², Kerstin Luhn³, Georgi Shukarev³, Macaya Douoguih³, Matthew D Snape¹

Affiliations

Affiliations

¹ Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
² Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
³ Janssen, Leiden, the Netherlands.

PMID: 28291882
DOI: 10.1001/jama.2016.20644

Clinical Trial

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year

Rebecca L Winslow et al. JAMA. 2017.

. 2017 Mar 14;317(10):1075-1077.

doi: 10.1001/jama.2016.20644.

Authors

Rebecca L Winslow¹, Iain D Milligan¹, Merryn Voysey², Kerstin Luhn³, Georgi Shukarev³, Macaya Douoguih³, Matthew D Snape¹

Affiliations

¹ Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
² Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
³ Janssen, Leiden, the Netherlands.

PMID: 28291882
DOI: 10.1001/jama.2016.20644

No abstract available

PubMed Disclaimer

Similar articles

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, Nuthall E, Voysey M, Silva-Reyes L, McElrath MJ, De Rosa SC, Frahm N, Cohen KW, Shukarev G, Orzabal N, van Duijnhoven W, Truyers C, Bachmayer N, Splinter D, Samy N, Pau MG, Schuitemaker H, Luhn K, Callendret B, Van Hoof J, Douoguih M, Ewer K, Angus B, Pollard AJ, Snape MD. Milligan ID, et al. JAMA. 2016 Apr 19;315(15):1610-23. doi: 10.1001/jama.2016.4218. JAMA. 2016. PMID: 27092831 Clinical Trial.
Adenovirus-vectored Ebola vaccines.
Gilbert SC. Gilbert SC. Expert Rev Vaccines. 2015;14(10):1347-57. doi: 10.1586/14760584.2015.1077122. Epub 2015 Aug 11. Expert Rev Vaccines. 2015. PMID: 26289977 Review.
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY. Wang D, et al. J Virol. 2006 Mar;80(6):2738-46. doi: 10.1128/JVI.80.6.2738-2746.2006. J Virol. 2006. PMID: 16501083 Free PMC article.
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team. Ledgerwood JE, et al. Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27. Vaccine. 2010. PMID: 21034824 Clinical Trial.
Immunology of protection from Ebola virus infection.
Krause PR, Bryant PR, Clark T, Dempsey W, Henchal E, Michael NL, Regules JA, Gruber MF. Krause PR, et al. Sci Transl Med. 2015 May 6;7(286):286ps11. doi: 10.1126/scitranslmed.aaa8202. Sci Transl Med. 2015. PMID: 25947159 Review.

See all similar articles

Cited by

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Alexandre M, Prague M, McLean C, Bockstal V, Douoguih M, Thiébaut R; EBOVAC 1 and EBOVAC 2 Consortia. Alexandre M, et al. NPJ Vaccines. 2023 Nov 8;8(1):174. doi: 10.1038/s41541-023-00767-y. NPJ Vaccines. 2023. PMID: 37940656 Free PMC article.
Ebola virus disease.
Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH. Jacob ST, et al. Nat Rev Dis Primers. 2020 Feb 20;6(1):13. doi: 10.1038/s41572-020-0147-3. Nat Rev Dis Primers. 2020. PMID: 32080199 Free PMC article. Review.
Ebola: Lessons on Vaccine Development.
Feldmann H, Feldmann F, Marzi A. Feldmann H, et al. Annu Rev Microbiol. 2018 Sep 8;72:423-446. doi: 10.1146/annurev-micro-090817-062414. Annu Rev Microbiol. 2018. PMID: 30200851 Free PMC article. Review.
Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection.
Longet S, Mellors J, Carroll MW, Tipton T. Longet S, et al. Front Immunol. 2021 Feb 19;11:599568. doi: 10.3389/fimmu.2020.599568. eCollection 2020. Front Immunol. 2021. PMID: 33679690 Free PMC article. Review.
Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies.
Masterson SG, Lobel L, Carroll MW, Wass MN, Michaelis M. Masterson SG, et al. Front Immunol. 2018 May 9;9:1025. doi: 10.3389/fimmu.2018.01025. eCollection 2018. Front Immunol. 2018. PMID: 29867992 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information